Epithalon

Epithalon (also spelled Epitalon or Epithalone) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by the St. Petersburg Institute of Bioregulation and Gerontology in Russia under the research direction of Vladimir Khavinson. It is the synthetic analog of Epithalamin, a polypeptide extract of the pineal gland. Khavinson's research group has dedicated decades to studying bioregulatory peptides — short peptides that modulate gene expression and tissue function — and Epithalon represents their most extensively studied and clinically applied compound in the aging and longevity field.

The defining biological mechanism that has generated the most scientific and popular interest in Epithalon is its ability to activate telomerase — the enzyme responsible for maintaining and extending telomere length. Telomeres are repetitive DNA sequences at the ends of chromosomes that protect chromosomal integrity during cell division. Each time a somatic cell divides, telomeres shorten slightly; when they become critically short, cells enter senescence (permanent cell cycle arrest) or apoptosis (programmed cell death). Telomere shortening is widely considered one of the primary molecular mechanisms of biological aging. Telomerase, which adds telomeric repeats back onto chromosome ends, is naturally active in stem cells and germ cells but is largely suppressed in most adult somatic cells. Epithalon has been shown in multiple in vitro studies to activate telomerase in human somatic cells, resulting in telomere elongation — a capability that has profound theoretical implications for cellular aging.

The published research base for Epithalon is unusual for a peptide in the longevity space: it includes not only in vitro and animal studies but also human clinical data from Khavinson's research group. Long-term studies conducted in elderly populations showed that Epithalon treatment was associated with reductions in mortality compared to control groups over follow-up periods of several years, alongside improvements in immune function, antioxidant status, hormonal parameters (including melatonin and cortisol normalization), and reductions in age-related disease incidence. These are observational findings from a specific research group rather than large multi-center randomized controlled trials, which means independent replication and larger studies are needed — but the existing human dataset is more substantive than most longevity compounds can claim.

Additional mechanisms identified in research include antioxidant activity (reduction of lipid peroxidation and improvement of antioxidant enzyme activity), normalization of pineal melatonin secretion, and gene expression regulatory effects documented through microarray studies showing modulation of hundreds of age-related genes. Practical protocols in the longevity community typically involve annual or twice-yearly short cycles (10–20 days) at 5–10 mg daily, given the evidence for durable rather than acute effects.